{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:42:48Z","timestamp":1792510968690,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T00:00:00Z","timestamp":1369267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00228-013-1518-4","type":"journal-article","created":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T07:09:06Z","timestamp":1369206546000},"page":"1689-1699","source":"Crossref","is-referenced-by-count":18,"title":["Available evidence and outcome of off-label use of rituximab in clinical practice"],"prefix":"10.1007","volume":"69","author":[{"given":"I.","family":"Dan\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Agust\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vallano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alerany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cort\u00e9s-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,23]]},"reference":[{"key":"1518_CR1","unstructured":"Real Decreto 1015\/2009, de 19 de junio, por el que se regula la disponibilidad de medicamentos en situaciones especiales. Bolet\u00edn Oficial del Estado. N\u00fam. 174 Lunes 20 de julio de 2009 Sec. I. P\u00e1g. 60904"},{"key":"1518_CR2","unstructured":"CatSalut (2010) Instrucci\u00f3 05\/2010. Utilitzaci\u00f3 de medicaments autoritzats en condicions diferents de les establertes en la fitxa t\u00e8cnica. Available at: http:\/\/www10.gencat.cat\/catsalut\/archivos\/instruccions\/instruccio_05_2010.pdf"},{"key":"1518_CR3","unstructured":"Alerany C, Agust\u00ed A, Dan\u00e9s I, Mart\u00ednez J, Fern\u00e1ndez J, Bosch JA (2010) Com adaptar-nos a la nova normativa d\u2019utilitzaci\u00f3 de medicaments en situacions especials: un exemple d\u2019iniciativa. e-farma;12. Available at: http:\/\/www10.gencat.net\/catsalut\/rsb\/farmacia\/efarma\/articles\/adaptacio_nova_normativa_vhebron.pdf"},{"key":"1518_CR4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47:115\u2013123","journal-title":"Semin Hematol"},{"key":"1518_CR5","unstructured":"European Medicines Agency. Mabthera: EPAR\u2014product information. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000165\/WC500025821.pdf"},{"key":"1518_CR6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/art.22629","volume":"57","author":"JZ Gillis","year":"2007","unstructured":"Gillis JZ, Dall\u2019era M, Gross A, Yazdany J, Davis J (2007) Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 57:538\u2013542","journal-title":"Arthritis Rheum"},{"key":"1518_CR7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2215\/CJN.04030808","volume":"4","author":"C Melander","year":"2009","unstructured":"Melander C, Sall\u00e9e M, Trolliet P, Candon S, Belenfant X, Daugas E, R\u00e9my P, Zarrouk V, Pillebout E, Jacquot C, Boffa JJ, Karras A, Masse V, Lesavre P, Elie C, Brocheriou I, Knebelmann B, No\u00ebl LH, Fakhouri F (2009) Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 4:579\u2013587","journal-title":"Clin J Am Soc Nephrol"},{"key":"1518_CR8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","volume":"11","author":"C D\u00edaz-Lagares","year":"2012","unstructured":"D\u00edaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Mart\u00ednez-Berriotxoa A, Garc\u00eda-Hern\u00e1ndez F, Callejas-Rubio JL, Rasc\u00f3n J, D\u2019Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA, UK-BIOGEAS Registry (2012) Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11:357\u2013364","journal-title":"Autoimmun Rev"},{"key":"1518_CR9","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","volume":"62","author":"B Terrier","year":"2010","unstructured":"Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harl\u00e9 JR, Hot A, Kahn JE, Lambotte O, Larroche C, L\u00e9one J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE, Club Rhumatismes et Inflammation (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62:2458\u20132466","journal-title":"Arthritis Rheum"},{"key":"1518_CR10","author":"M Trachana","year":"2011","unstructured":"Trachana M, Koutsonikoli A, Farmaki E, Printza N, Tzimouli V, Papachristou F (2011) Safety and efficacy of Rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int. doi: 10.1007\/s00296-011-2239-6","journal-title":"Rheumatol Int"},{"key":"1518_CR11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","volume":"18","author":"M Ramos-Casals","year":"2009","unstructured":"Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18:767\u2013776","journal-title":"Lupus"},{"key":"1518_CR12","first-page":"468","volume":"28","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Garc\u00eda-Hern\u00e1ndez FJ, de Ram\u00f3n E, Callejas JL, Mart\u00ednez-Berriotxoa A, Pallar\u00e9s L, Caminal-Montero L, Selva-O\u2019Callaghan A, Oristrell J, Hidalgo C, P\u00e9rez-Alvarez R, Mic\u00f3 ML, Medrano F, de laTorre G\u00f3mez R, D\u00edaz-Lagares C, Camps M, Ortego N, S\u00e1nchez-Rom\u00e1n J, BIOGEAS Study Group (2010) Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 28:468\u2013476","journal-title":"Clin Exp Rheumatol"},{"key":"1518_CR13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1445-5994.2009.01988.x","volume":"40","author":"SJ Butterly","year":"2010","unstructured":"Butterly SJ, Pillans P, Horn B, Miles R, Sturtevant J (2010) Off-label use of rituximab in a tertiary Queensland hospital. Int Intern Med J 40:443\u2013452","journal-title":"Int Intern Med J"},{"key":"1518_CR14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JOP.2010.000042","volume":"7","author":"EM Allen Van","year":"2011","unstructured":"Van Allen EM, Miyake T, Gunn N, Behler CM, Kohlwes J (2011) Off-label use of rituximab in a multipayer insurance system. J Oncol Pract 7:76\u201379","journal-title":"J Oncol Pract"},{"key":"1518_CR15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1130-6343(09)72973-3","volume":"33","author":"MC Conde Garc\u00eda","year":"2009","unstructured":"Conde Garc\u00eda MC, Fern\u00e1ndez Feijoo MA, Calleja Hern\u00e1ndez MA (2009) Estudio de adecuaci\u00f3n a la ficha t\u00e9cnica, efectividad, seguridad y coste del rituximab en un hospital de tercer nivel. Farm Hosp 33:305\u2013311","journal-title":"Farm Hosp"},{"key":"1518_CR16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"1518_CR17","unstructured":"Oxford Centre for Evidence-based Medicine (2009) Levels of evidence. Available at: http:\/\/www.cebm.net\/?o=1025 . Accessed 12 Sept 2012"},{"key":"1518_CR18","unstructured":"U.S. National Institutes of Health. Clinicaltrials.gov. Available at: http:\/\/clinicaltrials.gov\/ct2\/home Accessed 12 Sept 2012"},{"key":"1518_CR19","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706\u2013714","journal-title":"J Natl Cancer Inst"},{"key":"1518_CR20","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","volume":"28","author":"T Robak","year":"2010","unstructured":"Robak T, Dmoszynska A, Solal-C\u00e9ligny P, Zyuzgin I, Ganly PS, Dartigeas C, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756\u20131765","journal-title":"J Clin Oncol"},{"key":"1518_CR21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"1518_CR22","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferm\u00e9 C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 23:4117\u20134126","journal-title":"J Clin Oncol"},{"key":"1518_CR23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, L\u00f3pez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379\u2013391","journal-title":"Lancet Oncol"},{"key":"1518_CR24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Proch\u00e1zka V, Di Raimondo F, Ribrag V, Uppenkamp M, Andr\u00e9 M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH (2012) Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520\u2013531","journal-title":"N Engl J Med"},{"key":"1518_CR25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222\u2013233","journal-title":"Arthritis Rheum"},{"key":"1518_CR26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.semarthrit.2011.06.004","volume":"41","author":"J Narv\u00e1ez","year":"2011","unstructured":"Narv\u00e1ez J, R\u00edos-Rodr\u00edguez V, de la Fuente D, Estrada P, L\u00f3pez-Vives L, G\u00f3mez-Vaquero C, Nolla JM (2011) Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum 41:364\u2013372","journal-title":"Semin Arthritis Rheum"},{"key":"1518_CR27","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215\u20131226","journal-title":"Arthritis Rheum"},{"key":"1518_CR28","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/art.34362","volume":"64","author":"L Lightstone","year":"2012","unstructured":"Lightstone L (2012) The landscape after LUNAR: Rituximab\u2019s crater-filled path. Arthritis Rheum 64:962\u2013965","journal-title":"Arthritis Rheum"},{"key":"1518_CR29","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","volume":"115","author":"F Zaja","year":"2010","unstructured":"Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R (2010) Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 115:2755\u20132762","journal-title":"Blood"},{"key":"1518_CR30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","volume":"146","author":"DM Arnold","year":"2007","unstructured":"Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146:25\u201333","journal-title":"Ann Intern Med"},{"key":"1518_CR31","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2215\/CJN.05231008","volume":"4","author":"AS Bomback","year":"2009","unstructured":"Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH (2009) Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 4:734\u2013744","journal-title":"Clin J Am Soc Nephrol"},{"key":"1518_CR32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jama.297.7.683","volume":"297","author":"T Hampton","year":"2007","unstructured":"Hampton T (2007) Experts weigh in on promotion, prescription of off-label drugs. JAMA 297:683\u2013684","journal-title":"JAMA"},{"key":"1518_CR33","unstructured":"American Cancer Society. Off-label drug use. Available at: http:\/\/www.cancer.org\/Treatment\/TreatmentsandSideEffects\/TreatmentTypes\/Chemotherapy\/off-label-drug-use . Accessed 11 Nov 2012"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1518-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-013-1518-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1518-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:49:03Z","timestamp":1558702143000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-013-1518-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,23]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1007\/s00228-013-1518-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,23]]}}}